Francisco Kerdel

Francisco Kerdel

Auto-generated profile, based on publicly available information

Francisco Kerdel

Florida Academic Centers Research and Education, Coral Gables, Florida, USA

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2020 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
AGAlice Gottlieb
Alice Gottlieb
NNNicola E. Natsis
Nicola E. Natsis
FKFrancisco Kerdel
Francisco Kerdel
SFSeth Forman
Seth Forman
EGEdgar Gonzalez
Edgar Gonzalez
JSJohn Simard
John Simard

1 November 2002 in Archives of Dermatology
Verified
Journal Article
Open access
PDF file
JTJennifer T. Trent
Jennifer T. Trent
PRPaolo Romanelli
Paolo Romanelli
FKFrancisco A. Kerdel
Francisco A. Kerdel
A 56-year-old man presented with multiple red-violaceous firm, nontender nodules and plaques on the left frontal and parietal areas of his scalp (Figure 1). The

1 April 1990 in Journal of Investigative Dermatology
Verified
Journal Article
Open access
DBDonald V. Belsito
Donald V. Belsito
FKFrancisco A. Kerdel
Francisco A. Kerdel
JPJerome Potozkin
Jerome Potozkin
NSNicholas A. Soter
Nicholas A. Soter
BALB/c mice were treated with cimetidine (100 mg/kg) or saline, intraperitoneally, twice daily, from days 0-2 or days 7-9 after sensitization with 0.1%, 2,4,6-trinitro-1-chlorobenzene (TNCB) on day 0. On day 7, the mice were challenged with 1% TNCB to one ear. Ear swelling responses (as an index of sensitization), serum histamine levels, and biopsy specimens of challenged ears were evaluated in groups of cimetidine- or saline-treated mice at 0, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, and 48 h after challenge. Additional controls included mice injected with saline or cimetidine and challenged with, but not sensitized to, TNCB (irritant controls). Treatment with cimetidine during the induction but not the elicitation of allergic contact hypersensitivity (ACH) produced a significant enhancement of the response throughout the first 48 h. There was no effect of cimetidine on antigen-presenting cells within the epidermis which might account for this enhancement. Similarly, no difference in mast cell morphology or serum histamine levels between cimetidine- and saline-treated groups was observed. Histologically, the cimetidine-treated animals showed a more intense cellular infiltrate, which was most noticeable at 24 to 48 h, at which time numerous subcorneal and perifollicular neutrophilic abscesses were observed. To further investigate the mechanism of action of cimetidine, mice were injected with cyclophosphamide (150 mg/kg) 2 d prior to sensitization. Mice treated with cyclophosphamide alone or in combination with cimetidine showed no additive or synergistic effect upon the ear swelling response. We conclude that enhancement of ACH by cimetidine is independent of any effect on mast cells or antigen-presenting cells, but may relate to a cimetidine-induced inhibition of the induction of T-suppressor cells at the time of sensitization.

12 September 2012
Verified
Reference Entry
Closed access
PDF file
JIJohn R Ingram
John R Ingram
NDNemesha Desai
Nemesha Desai
AKAnneke C Kai
Anneke C Kai
SCSer Ling Chua
Ser Ling Chua
PWPick-Ngor Woo
Pick-Ngor Woo
VPVincent Piguet
Vincent Piguet

21 October 2019 in Journal of Dermatological Treatment
Verified
Journal Article
Open access
LPLuis Puig
Luis Puig
JWJashin J. Wu
Jashin J. Wu
MGMelinda Gooderham
Melinda Gooderham
YYYin You
Yin You
YSYaung-Kaung Shen
Yaung-Kaung Shen
FKFrancisco Kerdel
Francisco Kerdel
Introduction: In VOYAGE 1 (NCT02207231) and VOYAGE 2 (NCT02207244), guselkumab, an interleukin-23 blocker, was safe and effective in patients with moderate-to-severe plaque psoriasis. Methods: Patients who self-identified as Hispanic (n = 117) or non-Hispanic (n = 1686) were randomized to guselkumab, placebo, or adalimumab. Efficacy assessments included Psoriasis Area and Severity Index (PASI), Investigator’s Global Assessment (IGA), and Dermatology Life Quality Index (DLQI). Results: At week 16, treatment differences for guselkumab versus placebo in the Hispanic and non-Hispanic populations were 67.4 (95% confidence interval 50.4, 84.4) and 77.2 (73.5, 80.8) percentage points for IGA 0/1 and 59.2 (41.9, 76.4) and 69.2 (65.7, 72.7) percentage points for PASI 90, respectively. Treatment differences for guselkumab versus adalimumab were 25.9 (6.5, 45.3) and 17.5 (12.8, 22.3) percentage points for IGA 0/1 and 21.4 (-0.1, 42.9) and 23.5 (18.2, 28.9) percentage points for PASI 90, respectively. Week 24 results were similar. Adverse event frequency was greater in adalimumab- versus guselkumab-treated patients in the Hispanic population only through weeks 16 and 28. In both populations, DLQI 0/1 responses were greater in guselkumab-treated versus placebo- and adalimumab-treated patients at week 16 and versus adalimumab-treated patients at week 24. Conclusions: Guselkumab safety and efficacy were consistent between Hispanic and non-Hispanic populations.

1 July 1992 in Dermatologic Clinics
Verified
Journal Article
Closed access
FKFrancisco Kerdel
Francisco Kerdel
JGJane Grant-Kels
Jane Grant-Kels
MRMarti Jill Rothe
Marti Jill Rothe
BKBarry D. Kels
Barry D. Kels